Jennifer Munson named director of Fralin Biomedical Research Institute at VTC's Cancer Research Center

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, a biotechnology company developing next-generation T cell receptor-based therapies in oncology, announced that they have entered into a collaboration and license agreement to advance a novel in vivo approach to cell therapy for the treatment of solid tumors.

November 14, 2025

Vol.51 No.42

Clinical Roundup

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

Using cell cultures and animal models, researchers from the USC Norris Comprehensive Cancer Center at Keck School of Medicine of USC showed that next-generation CAR T cells can safely and effectively shrink solid tumors.

October 10, 2025

Vol.51 No.37

Drugs & Targets

FDA approves Keytruda Qlex injection for subcutaneous use in 38 tumor indications

FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) Sept. 19 for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab.

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.

September 19, 2025

Vol.51 No.34

In Brief

Kai Tsao appointed system chief of solid tumor oncology at Northwell

Kai Tsao was named system chief of solid tumor oncology, at the Northwell Cancer Institute.

September 05, 2025

Vol.51 No.32

Clinical Roundup

T cells and B cells join to fight solid tumors, Winship study finds

T helper 17 cells and B cells can work in concert to spark long-lasting protection against solid tumors, a research team at Winship Cancer Institute of Emory University found.

August 01, 2025

Vol.51 No.30

Jennifer Munson named director of Fralin Biomedical Research Institute at VTC’s Cancer Research Center

YOU MAY BE INTERESTED IN

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

FDA approves Keytruda Qlex injection for subcutaneous use in 38 tumor indications

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Kai Tsao appointed system chief of solid tumor oncology at Northwell

T cells and B cells join to fight solid tumors, Winship study finds

Renew today!

Subscriber content

Never miss an issue!

Login